Pro Medicus (ASX: PME) is an Australian-listed company in the Healthcare sector with a market capitalisation of $21.90B and the 37th-largest security on the ASX by market capitalisation. The PME share price is $209.63, up 1.29% today and down 31.80% over the past 12 months. Shares have traded between $107.75 and $336.00 over the past 52 weeks. PME trades on a price-to-earnings ratio of 33.67, above the Healthcare sector median of 10.89, and pays a trailing dividend yield of 0.14%. In its most recent reported period (ending 31 Dec 2025), Pro Medicus reported revenue of $124.8M and a net profit of $171.2M (137.2% margin).
About Pro Medicus Limited
Established in 1983 and based in Richmond, Australia, Pro Medicus Limited is a leading provider of medical imaging software and services. The company develops and delivers advanced solutions to hospitals, diagnostic imaging groups, and other healthcare organizations across Australia, North America, and Europe. Their core offerings include proprietary Radiology Information Systems (RIS), which streamline practice management and come with comprehensive support, training, installation, and professional services. Pro Medicus also operates Promedicus.net, an e-health platform, and supplies sophisticated imaging software designed to provide radiologists and clinicians with powerful visualization capabilities for 2D, 3D, and 4D medical images. This suite of tools is further enhanced by Picture Archiving and Communication System (PACS)/digital imaging software and integration products. Additionally, they offer mobile applications like Visage Ease Pro, which enables remote interpretation of diagnostic imaging studies stored on a Visage 7 server. Key product brands include Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease.
